跳至主要内容
临床试验/IRCT201206131030N10
IRCT201206131030N10已完成2 期

Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer

Iran Polymer and petrochemical institute0 个研究点目标入组 98 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
98

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
Male

入选标准

  • 1-Paetient with metastatic prostate cancer who examined by paraclinical diagnostics. (i.e.: needle biopsy of prostate, pathologic trans rectal sonography bone scan, CT-scan and MRI) and assessd their bone and viscera; 2- Must be Iranian; 3-Signed the testimonial form by own awareness. 4-Confidency of patient cooperation with administering drug; 5-Assitance of patient to come with scheduled program. Exclusion criteria: 1-Disorder in hypothalamus-hypophysis-gonadal axis; 2-Previous treatment with GnRH analog or other hormonal treatment or chemotherapy in last three month; 3-Radioteraohy in last two month; 4-Malignant with active origin; 5-Need to adjuvant treatment; 6-Urinary obstruction or spinal cord compression; 7- Administering with other drug (cooperating with another study); 8- Dissatisfaction of patient; 9-Probability of impossibility of following by patient; 10-drug addiction; 11- allergy to GnRH analogs or any kind of GnRH.

排除标准

  • 未提供

研究者

发起方
Iran Polymer and petrochemical institute

相似试验